What Macleods Pharmaceuticals Ltd. does

Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian pharmaceutical company headquartered in Mumbai that develops, manufactures, and markets generic medicines across more than 19 therapeutic categories, including anti-tuberculosis drugs, antiretrovirals, anti-infectives, cardiovascular, central nervous system, diabetology, oncology, and peptides. The company operates its own active pharmaceutical ingredient (API) and formulations development facilities, supported by a 250-bed bioequivalence centre equipped with NABL-accredited clinical laboratories, 20 LC/MS/MS instruments, and SAS-based statistical analysis for crossover, replicate, parallel, and steady-state bioequivalence studies. Manufacturing facilities are inspected and approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, with 185 ANDAs filed and 100 approved at the USFDA as of August 2023 and WHO prequalified medicines in the portfolio.

Macleods distributes products in over 170 countries through a mix of wholly-owned subsidiaries (USA, UK, Germany, Spain, South Africa, Ukraine, Kazakhstan, Malaysia, Philippines, and Nigeria), branch offices, a joint venture in Indonesia (PT Sampharindo Retroviral Indonesia, established 2017), and out-licensing arrangements with European distributors. Its customer base spans government health programmes such as India's National TB Elimination Programme and the Global Drug Facility, public healthcare systems, private hospitals and pharmacies, and institutional procurement channels. Direct field sales forces call on physicians, specialists, hospitals, and pharmacies across multiple markets, supplemented by participation in medical congresses and direct healthcare-professional communications.

Revenue is generated predominantly through one-time sales of generic pharmaceutical products across both regulated (US, UK, EU) and emerging (South Africa, MENA, CIS, Southeast Asia) markets, with pricing not publicly disclosed. The company has scaled through retained earnings rather than external funding, with 18,000+ employees globally. Notable recent strategic activity includes entry into the South Africa private sector (November 2022), a February 2026 Delhi High Court ruling favorable to Macleods in a Linagliptin patent challenge, and the appointment of a new group CFO in February 2026. The founder, Dr. Rajendra Agarwal, continues as Managing Director.

Name

Macleods Pharmaceuticals Ltd.

Legal name

Macleods Pharmaceuticals Ltd.

Website

https://macleodspharma.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Macleods Pharmaceuticals Ltd. is a privately held, vertically integrated Indian generic pharmaceutical company that develops, manufactures, and distributes medicines across 19+ therapeutic areas to public health programmes, hospitals, and pharmacies in 170+ countries through subsidiaries and out-licensing partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF), Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

Keywords

• Generic pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Bioequivalence studies
• Antiretroviral medications
• Anti-tuberculosis drugs

Headquarters

HQ city

Andheri

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Products: Revenue generated from manufacturing and selling generic pharmaceutical formulations across multiple therapeutic categories including anti-TB, ARVs, cardiovascular, anti-infectives, CNS, diabetology, oncology, and other treatments. Products are sold in over 170 countries globally through direct presence in multiple markets.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical manufacturer that develops, produces, and sells generic formulations and Active Pharmaceutical Ingredients (APIs) across more than 19 therapeutic categories including anti-tuberculosis, antiretrovirals, cardiovascular, central nervous system, diabetology, anti-infectives, anti-malarials, oncology, and peptides. The company operates R&D, bioanalytical and 250-bed bioequivalence centres, and manufactures products at facilities approved by USFDA, WHO Geneva, UK MHRA, and ANVISA, supplying generic medicines through direct subsidiaries, field sales, and out-licensing distributors in over 170 countries.

Product overview

Macleods Pharmaceuticals Ltd. is a vertically integrated global pharmaceutical organization and one of the top 10 companies in the Indian pharmaceutical market. The company provides generic pharmaceutical products across multiple therapeutic areas including Anti-Infectives, Anti-Virals, Anti-Retrovirals (ARVs), Blood Related, Cardiology, Central Nervous System, Diabetology, Endocrinology, Gastroenterology, Pain Management, Respiratory, Urology, Anti-Tuberculosis (Adult and Pediatric), Anti-Malaria, Oncology, and Peptides. The company operates R&D and bioequivalence centers with 250 beds, manufactures Active Pharmaceutical Ingredients (APIs) and formulations, and distributes products globally through subsidiaries and offices in India, USA, UK, Germany, Spain, South Africa, Kazakhstan, Ukraine, Indonesia, MENA region, and the Philippines. The product portfolio includes branded generics like Rivaroxaban, Apixaban, Simarax, and Emtricitabine/Tenofovir, as well as extensive generic formulations across all therapeutic categories.

Differentiator

Problem solved

Functional benefit

Brands

• Simarax: Sildenafil 50 mg film-coated tablets for erectile dysfunction, marketed in the UK market.

Products and services

• USA Generic Pharmaceutical Product Portfolio Generic pharmaceutical formulations distributed in the United States market across cardiovascular, central nervous system, anti-infective, and respiratory therapeutic categories, including products such as Acyclovir Ointment, Amlodipine/Olmesartan tablets, and Aripiprazole tablets. Marketed through Macleods Pharma USA Limited. As of August 31, 2023, Macleods had 185 ANDAs filed with USFDA, of which 100 were approved.
• MENA Generic Pharmaceutical Product Portfolio Generic pharmaceutical products for Middle East and North Africa markets covering Anti-Infectives, Anti-Virals, Anti-Retrovirals, Blood Related, Cardiology, CNS, Diabetology, Endocrinology, Gastroenterology, Pain Management, Respiratory, Urology, Anti-Tuberculosis (Adult and Pediatric), Anti-Malaria, Oncology, and Peptides. Distributed through Macleods' MENA operations across Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Jordan, Lebanon, Syria, Israel, Egypt, and other regional markets.
• Kazakhstan Generic Pharmaceutical Product Portfolio Products registered in Kazakhstan including Mucogen, Trimspa, Rabemac, Nupenta, Valmac, Clopi-75, Mucitus, Rapitus, and Zithrox-Macleods, spanning gastroenterology, cardiology, pulmonology, and infections. Distributed through Macleods Pharma Kazakhstan branch office with over 100 employees across major cities and regions.
• Rivaroxaban generic anticoagulant Generic anticoagulant equivalent to Bayer's Xarelto, available in 2.5mg, 10mg, 15mg, and 20mg film-coated tablets for Germany and MENA markets. Used for the prevention and treatment of thromboembolic disorders.
• Apixaban generic anticoagulant Generic anticoagulant equivalent to Bristol-Myers Squibb's Eliquis, available in 2.5mg and 5mg tablets for Germany and MENA markets. Used for the prevention and treatment of thromboembolic disorders.
• Simarax (Sildenafil 50mg) Macleods' UK brand for Sildenafil 50mg film-coated tablets indicated for erectile dysfunction. Marketed in the United Kingdom through Macleods Pharma UK Limited.
• Emtricitabine/Tenofovir Disoproxil Fumarate 200mg/245mg Generic HIV medication equivalent to Gilead's Truvada, supplied as 200mg/245mg film-coated tablets for PrEP (pre-exposure prophylaxis) in the UK market through Macleods Pharma UK Limited.
• Antiretroviral therapy products (PT Sampharindo Retroviral Indonesia) Antiretroviral products developed and supplied through PT Sampharindo Retroviral Indonesia, a Macleods joint venture established in 2017 in Semarang, Central Java. Focused on developing new molecules for antiretroviral therapy and overcoming resistance challenges, including Abacavir, Atazanavir/Ritonavir, Lamivudine, Lopinavir/Ritonavir, Tenofovir, and Zidovudine formulations.
• Active Pharmaceutical Ingredients (APIs) In-house manufactured Active Pharmaceutical Ingredients (APIs) developed by Macleods' R&D centres, transitioning from basic APIs to high-potency APIs and CDMO services under India's Production Linked Incentive (PLI) scheme. APIs support both Macleods' own formulations portfolio and contract supply.

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Government of India (PLI Scheme)coreStrategic or Co-development PartnerMacleods Pharma completed projects under the Production Linked Incentive (PLI) scheme promoted by the Government of India to promote domestic manufacturing of pharmaceuticals. The company is transitioning from basic API manufacturing to high-potency APIs, CDMO services, and formulations as part of this initiative.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Torrent Pharmaceuticals: Torrent is an Indian mid-tier generic pharmaceutical manufacturer with strong presence in cardiovascular and CNS generics across India and emerging markets, similar therapeutic focus to Macleods.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest pharmaceutical company and a vertically integrated generic and specialty pharma manufacturer with a comparable global footprint. It competes with Macleods in cardiovascular, CNS, and anti-infective generics across regulated and emerging markets.
• Dr. Reddy's Laboratories: Dr. Reddy's is a leading Indian generic pharmaceutical company with strong API and formulations businesses, significant US ANDA portfolio, and global distribution. It competes directly with Macleods in generic formulations across cardiovascular, CNS, and oncology categories.
• Lupin Limited: Lupin is an Indian pharmaceutical company with comparable scale, a substantial US generics franchise, and API manufacturing capabilities. It overlaps with Macleods in cardiovascular, anti-TB, and other therapeutic generics across global markets.
• Zydus Lifesciences: Zydus is an Indian pharmaceutical company with vertically integrated API and formulations operations, including biosimilars, comparable to Macleods' integrated model. It competes in cardiovascular, anti-infectives, and other generics globally.
• Aurobindo Pharma: Aurobindo is a top-5 Indian generic pharmaceutical manufacturer with strong ARV, anti-infective, and US generics franchises. It competes with Macleods across therapeutic categories, particularly in ARVs and government/public health supply contracts.
• Cipla Limited: Cipla is a top-tier Indian generic pharmaceutical manufacturer with comparable global presence, strong anti-TB/ARV franchises, and USFDA-approved facilities. It directly competes with Macleods across therapeutic categories, geographies, and government supply programs, with overlapping leadership pedigrees (multiple Macleods SA executives came from Cipla).
• Glenmark Pharmaceuticals: Glenmark is an Indian generic and specialty pharmaceutical company with comparable India-anchored global operations. It overlaps with Macleods in respiratory, dermatology, and cardiovascular generics.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive US and global operations. It competes with Macleods in cardiovascular, CNS, and anti-infective generics across regulated markets.
• Sandoz (Novartis): Sandoz is the global leader in generic pharmaceuticals, with a much larger global footprint and broader portfolio. It competes with Macleods in generic formulations across all major therapeutic categories and geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/macleods-pharmaceuticals-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macleods Pharmaceuticals Ltd.